Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

BAFF-R (mouse):Fc (human), (recombinant)

ALX-522-080-C050 50 µg 446.00 USD
Do you need bulk/larger quantities?

Product Details

Alternative Name:TNFRSF 13C, BR3, BlySR3, CD268
MW:~35kDa (SDS-PAGE).
Source:Produced in HEK 293 cells. The extracellular domain of mouse BAFF-R (aa 2-70) is fused at the C-terminus to a linker peptide (10 aa) and the Fc portion of human IgG1.
UniProt ID:Q9D8D0
Gene/Protein Identifier:A002648 (UCSD Signaling Gateway ID)
Concentration:1mg/ml (after reconstitution).
Formulation:Lyophilized. Contains PBS.
Purity:≥95% (SDS-PAGE)
Endotoxin Content:<0.1EU/µg purified protein (LAL test; BioWhittaker).
Specificity:Binds mouse and human BAFF.
Applications:ELISA, Flow Cytometry, FUNC
Application Notes:ELISA: binds to BAFF.
Flow Cytometry: Detection of membrane-bound mouse and human BAFF in combination with fluorescently labelled Ab to IgG1.
Reconstitution:Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein.
Shipping:Shipped on Blue Ice
Long Term Storage:-20°C
Use/Stability:Stable for at least 6 months after receipt when stored at -20°C.
Handling:Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
Scientific Background:BAFF-R:Fc is 10-fold more efficacious than BCMA:Fc for blocking BAFF-induced B cell proliferation in vitro and for blocking BAFF-mediated survival of mouse splenic B lymphocytes in vivo. Thus BAFF-R:Fc becomes a promising therapeutic candidate as a BAFF-neutralizing compound in autoimmune disease intervention. Historical data has shown that BAFF-R blocks the binding of mouse and human BAFF to their BAFF-receptors, inhibiting BAFF-mediated splenocyte survival.
Regulatory Status:RUO - Research Use Only
BAFF-R (mouse):Fc (human), (recombinant) Flow Cytometry
Inhibition of rhsBAFF-mediated splenocyte survival.
rmBAFF-R:Fc inhibits rhsBAFF-mediated activation of freshly isolated splenocytes. Concentration of rmBAFF-R:Fc (Prod. Nr. ALX-522-080) to achieve complete inhibition depends on the concentration of rhsBAFF (Prod. Nr. ALX-522-025) used. A ratio (rhsBAFF:rmBAFF-R:Fc) 1:50 and higher is recommended.
Method: On day 0 splenocytes were isolated from a freshly collected C57Bl6 spleen. An aliquot of the splenocytes was analyzed on FACS, and B cells were gated on the SSC-FSC panel. FACS settings were saved. The rest of the cells was put in culture with media alone, with the indicated concentration of rhsBAFF alone or in the presence of an excess of rmBAFF-R:Fc (50µg/ml). After three days in culture, cells were again analyzed on FACS with the saved setting. Splenocytes survival index (=ratio of %living/%dead cells) was calculated and plotted."
Please mouse over
BAFF-R (mouse):Fc (human), (recombinant) Flow Cytometry

Product Literature References

BAFF production by antigen-presenting cells provides T cell co-stimulation: B. Huard, et al.; Int. Immunol. 16, 467 (2004), Abstract;

General Literature References

BAFF production by antigen-presenting cells provides T cell co-stimulation: B. Huard, et al.; Int. Immunol. 16, 467 (2004), Abstract;
Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF: M. Pelletier, et al.; J. Biol. Chem. 278, 33127 (2003), Abstract;

Related Products

Control:Fc fusion protein (human), (recombinant) 

Negative control for Fc chimeric proteins
Produced in HEK 293 cells. The extracellular domain of mutated hThy-1, hThy-1 (RLE) (aa 20-130), is fused to the Fc portion of human IgG1. The integrin binding sequence RLD of hThy-1 has been changed to RLE abolishing the binding of integrins., ≥90% (SDS-PAGE) | Print as PDF
ALX-203-004-C050 50 µg 447.00 USD
Do you need bulk/larger quantities?

Product Toolbox


Certificate of Analysis


By target:
BAFF receptor
By biological activity:
BAFF receptor Recombinant protein
By catalog section:


Technical Service
Customer Service

Recommend this page

Keep in touch

©2021 Enzo Life Sciences, Inc.,